6 news items
S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
HEPA
MTTR
22 Apr 24
down 28% to $1.51 after the company announced that it began wind-down activities in its Phase 2b “ASCEND-NASH Trial
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
HEPA
22 Apr 24
. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAOI
AGBA
AGRI
22 Apr 24
the company announced that it began wind-down activities in its Phase 2b “ASCEND-NASH Trial.
Akso Health Group
Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"
HEPA
19 Apr 24
"We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints," said
Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b 'ASCEND-NASH' Trial
HEPA
19 Apr 24
liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives
9tddscg ofaqa2njotz231h3jcuamp64x9y5adl86ok
HEPA
19 Apr 24
"), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic
- Prev
- 1
- Next